Nutriband Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.56
- Today's High:
- $2.86
- Open Price:
- $2.86
- 52W Low:
- $1.92
- 52W High:
- $5.15
- Prev. Close:
- $2.85
- Volume:
- 2529
Company Statistics
- Market Cap.:
- $24.91 million
- Book Value:
- 0.986
- Revenue TTM:
- $2.08 million
- Operating Margin TTM:
- -215.52%
- Gross Profit TTM:
- $750409
- Profit Margin:
- -231.34%
- Return on Assets TTM:
- -27.1%
- Return on Equity TTM:
- -51.16%
Company Profile
Nutriband Inc had its IPO on 2017-11-30 under the ticker symbol NTRB.
The company operates in the Healthcare sector and Biotechnology industry. Nutriband Inc has a staff strength of 0 employees.
Stock update
Shares of Nutriband Inc opened at $2.86 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.56 - $2.86, and closed at $2.56.
This is a -10.18% slip from the previous day's closing price.
A total volume of 2,529 shares were traded at the close of the day’s session.
In the last one week, shares of Nutriband Inc have slipped by -19.5%.
Nutriband Inc's Key Ratios
Nutriband Inc has a market cap of $24.91 million, indicating a price to book ratio of 3.0748 and a price to sales ratio of 14.1413.
In the last 12-months Nutriband Inc’s revenue was $2.08 million with a gross profit of $750409 and an EBITDA of $-4151989. The EBITDA ratio measures Nutriband Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nutriband Inc’s operating margin was -215.52% while its return on assets stood at -27.1% with a return of equity of -51.16%.
In Q1.3333333333333, Nutriband Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 0.2%.
Nutriband Inc’s PE and PEG Ratio
- Forward PE
- 370.3704
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.58 per share while it has a forward price to earnings multiple of 370.3704 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nutriband Inc’s profitability.
Nutriband Inc stock is trading at a EV to sales ratio of 13.3594 and a EV to EBITDA ratio of -4.4217. Its price to sales ratio in the trailing 12-months stood at 14.1413.
Nutriband Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $9.87 million
- Total Liabilities
- $874127.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $2624
- Dividend Payout Ratio
- 0%
Nutriband Inc ended 2024 with $9.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.87 million while shareholder equity stood at $6.89 million.
Nutriband Inc ended 2024 with $0 in deferred long-term liabilities, $874127.00 in other current liabilities, 7833.00 in common stock, $-24339107.00 in retained earnings and $5.02 million in goodwill. Its cash balance stood at $2.33 million and cash and short-term investments were $2.33 million. The company’s total short-term debt was $159,459 while long-term debt stood at $0.
Nutriband Inc’s total current assets stands at $3.27 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $223452.00 compared to accounts payable of $0 and inventory worth $156921.00.
In 2024, Nutriband Inc's operating cash flow was $0 while its capital expenditure stood at $2624.
Comparatively, Nutriband Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.56
- 52-Week High
- $5.15
- 52-Week Low
- $1.92
- Analyst Target Price
- $18
Nutriband Inc stock is currently trading at $2.56 per share. It touched a 52-week high of $5.15 and a 52-week low of $5.15. Analysts tracking the stock have a 12-month average target price of $18.
Its 50-day moving average was $3.45 and 200-day moving average was $3.45 The short ratio stood at 0.49 indicating a short percent outstanding of 0%.
Around 3514.5% of the company’s stock are held by insiders while 255% are held by institutions.
Frequently Asked Questions About Nutriband Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.